1） 日本排尿機能学会過活動膀胱診療ガイドライン 作成委員会：過活動膀胱診療ガイドライン 第2 版．RichHill Medical, 2015.
2） Abrams, P., L. Cardozo, M. Fall, D. Griffi ths, P. Rosier, U. Ulmsten, P. van Kerrebroeck, A. Victor, and A. Wein: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. American journal of obstetrics and gynecology, 187(1): 116–126, 2002.
3） Abrams, P., L. Cardozo, M. Fall, D. Griffi ths, P. Rosier, U. Ulmsten, P. van Kerrebroeck, A. Victor, and A. Wein: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourology and urodynamics, 21(2): 167–178, 2002.
4） Homma, Y., O. Yamaguchi, and K. Hayashi: Epidemiologic survey of lower urinary tract symptoms in Japan. Urology, 68(3): 560–564, 2006.
5） 吉田正貴，後藤百万，山上英臣，本間之夫：泌尿 器科・一般内科医および患者における過活動膀胱 治療の認識．泌尿器外科，25(12): 2425–2434，2012.
6） Yokoyama, O., M. Honda, T. Yamanishi, Y. Sekiguchi, K. Fujii, T. Nakayama, and T. Mogi: OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis). Int J Urol, 27(3): 227-234, 2020.
7） Nitti, V.W., R. Dmochowski, S. Herschorn, P. Sand, C. Thompson, C. Nardo, X. Yan, C. HaagMolkenteller, and E.S. Group: OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol, 189(6): 2186-2193, 2013.
8） Chapple, C., K.D. Sievert, S. MacDiarmid, V. Khullar, P. Radziszewski, C. Nardo, C. Thompson, J. Zhou, and C. Haag-Molkenteller: OnabotulinumtoxinA 100 U signifi cantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol, 64(2): 249– 256, 2013.
9） Noblett, K., S. Siegel, J. Mangel, T.L. Griebling, S.E. Sutherland, E.T. Bird, C. Comiter, D. Culkin, J. Bennett, S. Zylstra, F. Kan, and K.C. Berg: Results of a prospective, multicenter study evaluating quality of life, safety, and effi cacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn, 35(2): 246–251, 2016.
10） Chen, L.C. and H.C. Kuo: Pathophysiology of refractory overactive bladder. Low Urin Tract Symptoms, 11(4): 177–181, 2019.
11） Merrill, L., E.J. Gonzalez, B.M. Girard, and M.A. Vizzard: Receptors, channels, and signalling in the urothelial sensory system in the bladder. Nat Rev Urol, 13(4): 193–204, 2016.
12） Mochizuki, T., T. Sokabe, I. Araki, K. Fujishita, K. Shibasaki, K. Uchida, K. Naruse, S. Koizumi, M. Takeda, and M. Tominaga: The TRPV4 cation channel mediates stretch-evoked Ca2+ infl ux and ATP release in primary urothelial cell cultures. J Biol Chem, 284(32): 21257–21264, 2009.
13） Miyamoto, T., T. Mochizuki, H. Nakagomi, S. Kira, M. Watanabe, Y. Takayama, Y. Suzuki, S. Koizumi, M. Takeda, and M. Tominaga: Functional role for Piezo1 in stretch-evoked Ca(2)(+) infl ux and ATP release in urothelial cell cultures. J Biol Chem, 289(23): 16565–16575, 2014.
14） Shimura, H., T. Mitsui, S. Tsuchiya, T. Miyamoto, T. Ihara, S. Kira, H. Nakagomi, N. Sawada, Y. Imai, T. Mochizuki, and M. Takeda: Development of novel and non-invasive diagnostic markers for lower urinary tract symptoms using urothelial cells in voided urine. Neurourology and urodynamics, 37(3): 1137–1143, 2018.
15） Lee, D.Y., B.P. Bowen, and T.R. Northen: Mass spectrometry-based metabolomics, analysis of metabolite-protein interactions, and imaging. Biotechniques, 49(2): 557–565, 2010.
16） Shimura, H., T. Mitsui, S. Kira, T. Ihara, N. Sawada, H. Nakagomi, T. Miyamoto, S. Tsuchiya, M. Kanda, and M. Takeda: Metabolomic Analysis of Overactive Bladder in Male Patients: Identifi cation of Potential Metabolite Biomarkers. Urology, 118: 158–163, 2018.
17） Dawson, J. and M. Walters: Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol, 62(6): 633–644, 2006.
18） Waring, W.S., J.A. McKnight, D.J. Webb, and S.R. Maxwell: Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes, 55(11): 3127–3132, 2006.
19） Mitsui, T., S. Kira, T. Ihara, N. Sawada, H. Nakagomi, T. Miyamoto, H. Shimura, S. Tsuchiya, M. Kanda, and M. Takeda: Metabolism of fatty acids and bile acids in plasma is associated with overactive bladder in males: potential biomarkers and targets for novel treatments in a metabolomics analysis. Int Urol Nephrol, 52(2): 233–238, 2020.
20） Taoka, H., Y. Yokoyama, K. Morimoto, N. Kitamura, T. Tanigaki, Y. Takashina, K. Tsubota, and M. Watanabe: Role of bile acids in the regulation of the metabolic pathways. World J Diabetes, 7(13): 260–270, 2016.
21） Houten, S.M., M. Watanabe, and J. Auwerx: Endocrine functions of bile acids. EMBO J, 25(7): 1419–1425, 2006.
22） Chiang, J.Y.: Bile acid metabolism and signaling. Compr Physiol, 3(3): 1191–1212, 2013.
23） Kira, S., T. Miyamoto, S. Tsuchiya, H. Nakagomi, T. Ihara, N. Sawada, M. Takeda, and T. Mitsui: Potential targets for overactive bladder in older men based on urinary analysis of metabolomics. Urol Int, 2021, in press.
24） Kupelian, V., K.T. McVary, S.A. Kaplan, S.A. Hall, C.L. Link, L.P. Aiyer, P. Mollon, N. Tamimi, R.C. Rosen, and J.B. McKinlay: Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol, 182(2): 616–624, 2009; discussion 624–625.
25） Uzun, H. and O.U. Zorba: Metabolic syndrome in female patients with overactive bladder. Urology, 79(1): 72–75, 2012.
26） Ohgaki, K., K. Horiuchi, and Y. Kondo: Association between metabolic syndrome and male overactive bladder in a Japanese population based on three different sets of criteria for metabolic syndrome and the Overactive Bladder Symptom Score. Urology, 79(6): 1372–1378, 2012.
27） Kirby, M.G., A. Wagg, L. Cardozo, C. Chapple, D. Castro-Diaz, D. de Ridder, M. Espuna-Pons, F. Haab, C. Kelleher, H. Kolbl, I. Milsom, P. Van Kerrebroeck, M. Vierhout, S. Salvatore, and A. Tubaro: Overactive bladder: Is there a link to the metabolic syndrome in men? Neurourol Urodyn, 29(8): 1360–1364, 2010.
28） Vrijens, D., J. Drossaerts, G. van Koeveringe, P. Van Kerrebroeck, J. van Os, and C. Leue: Affective symptoms and the overactive bladder - a systematic review. J Psychosom Res, 78(2): 95–108, 2015.
29） Wrobel, A., U. Doboszewska, E. Rechberger, P. Wlaz, and T. Rechberger: SN003, a CRF1 receptor antagonist, attenuates depressive-like behavior and detrusor overactivity symptoms induced by 13-cis-retinoic acid in rats. Eur J Pharmacol, 812: 216–224, 2017.
30） Steers, W.D., S. Herschorn, K.J. Kreder, K. Moore, K. Strohbehn, I. Yalcin, R.C. Bump, and O.A.B.S.G.: Duloxetine, Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int, 100(2): 337–345, 2007.
31） Wrobel, A., E. Rechberger, and T. Rechberger: The infl uence of duloxetine on detrusor overactivity in rats with depression induced by 13-cisretinoic acid. Int Urogynecol J, 29(7): 987–995, 2018.
32） Hanna-Mitchell, A.T., D. Robinson, L. Cardozo, K. Everaert, and G.V. Petkov: Do we need to know more about the effects of hormones on lower urinary tract dysfunction? ICI-RS 2014. Neurourol Urodyn, 35(2): 299–303, 2016.
33） Lee, K.C.: Changes of muscarinic receptors and connexin-43 expression as a mechanism of overactive bladder in ovariectomized rats. World J Urol, 33(11): 1875–1879, 2015.
34） Portman, D.J., M.L. Gass, and P. Vulvovaginal Atrophy Terminology Consensus Conference: Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. J Sex Med, 11(12): 2865–2872, 2014.
35） Cody, J.D., M.L. Jacobs, K. Richardson, B. Moehrer, and A. Hextall: Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev, 10: CD001405, 2012.
36） Aragon, I.M., B. Herrera-Imbroda, M.I. QueipoOrtuno, E. Castillo, J.S. Del Moral, J. GomezMillan, G. Yucel, and M.F. Lara: The Urinary Tract Microbiome in Health and Disease. Eur Urol Focus, 4(1): 128–138, 2018.
37） Pearce, M.M., E.E. Hilt, A.B. Rosenfeld, M.J. Zilliox, K. Thomas-White, C. Fok, S. Kliethermes, P.C. Schreckenberger, L. Brubaker, X. Gai, and A.J. Wolfe: The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. mBio, 5(4): e01283-14, 2014.
38） Karstens, L., M. Asquith, S. Davin, P. Stauffer, D. Fair, W.T. Gregory, J.T. Rosenbaum, S.K. McWeeney, and R. Nardos: Does the Urinary Microbiome Play a Role in Urgency Urinary Incontinence and Its Severity? Front Cell Infect Microbiol, 6: 78, 2016.
39） Thomas-White, K.J., E.E. Hilt, C. Fok, M.M. Pearce, E.R. Mueller, S. Kliethermes, K. Jacobs, M.J. Zilliox, C. Brincat, T.K. Price, G. Kuffel, P. Schreckenberger, X. Gai, L. Brubaker, and A.J. Wolfe: Incontinence medication response relates to the female urinary microbiota. Int Urogynecol J, 27(5): 723–733, 2016.
40） Wu, P., Y. Chen, J. Zhao, G. Zhang, J. Chen, J. Wang, and H. Zhang: Urinary Microbiome and Psychological Factors in Women with Overactive Bladder. Front Cell Infect Microbiol, 7: 488, 2017.
41） Malykhina, A.P., J.J. Wyndaele, K.E. Andersson, S. De Wachter, and R.R. Dmochowski: Do the urinary bladder and large bowel interact, in sickness or in health? ICI-RS 2011. Neurourol Urodyn, 31(3): 352–358, 2012.
42） Kaplan, S.A., R. Dmochowski, B.D. Cash, Z.S. Kopp, S.J. Berriman, and V. Khullar: Systematic review of the relationship between bladder and bowel function: implications for patient management. Int J Clin Pract, 67(3): 205–216, 2013.
43） Persson, R., K.A. Wensaas, K. Hanevik, G.E. Eide, N. Langeland, and G. Rortveit: The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection. BMC Gastroenterol, 15: 66, 2015.
44） Caremel, R., H. Damon, A. Ruffi on, E. ChartierKastler, G. Gourcerol, F. Michot, J.F. Menard, P. Grise, and A.M. Leroi: Can sacral neuromodulation improve minor incontinence symptoms in doubly incontinent patients successfully treated for major incontinence symptoms? Urology, 79(1): 80–85, 2012.
45） Peyronnet, B., E. Mironska, C. Chapple, L. Cardozo, M. Oelke, R. Dmochowski, G. Amarenco, X. Game, R. Kirby, F. Van Der Aa, and J.N. Cornu: A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol, 75(6): 988–1000, 2019.
論文の公開元へ
